Table 1. Vaccine options for different restart types.

OPV formulation	Potential vaccine options for each OPV formulation
OPV1	mOPV1 nOPV1
OPV2	mOPV2 nOPV2
OPV3	mOPV3 nOPV3
OPV12	bOPV(S1,S2) or mOPV1/+mOPV2 bOPV(S1,N2) or mOPV1/+nOPV2 bOPV(N1,S2) or nOPV1/+mOPV2 bOPV(N1,N2) or nOPV1/+nOPV2
OPV13	bOPV (S1,S3) or mOPV1/+mOPV3 bOPV(N1,S3) or nOPV1/+mOPV3 bOPV(S1,N3) or mOPV1/+nOPV3 bOPV(N1,N3) or nOPV1/+nOPV3
OPV23	bOPV(S2,S3) or mOPV2/+mOPV3 bOPV(N2,S3) or nOPV2/+mOPV3 bOPV(S2,N3) or mOPV2/+nOPV3 bOPV(N2,N3) or nOPV2/+nOPV3
OPV123	tOPV                   or bOPV/+mOPV2               or mOPV1/+mOPV2/+mOPV3 tOPV(N1,S2,S3) or nOPV1/+bOPV(S2,S3)    or nOPV1/+mOPV2/+mOPV3 tOPV(S1,N2,S3) or nOPV2/+bOPV               or mOPV1/+nOPV2/+mOPV3 tOPV(S1,S2,N3) or nOPV3/+bOPV(S1,S2)     or mOPV1/+mOPV2/+nOPV3 tOPV(S1,N2,N3) or mOPV1/+bOPV(N2,N3) or mOPV1/+nOPV2/+nOPV3 tOPV(N1,S2,N3) or mOPV2/+bOPV(N1,N3) or nOPV1/+mOPV2/+nOPV3 tOPV(N1,N2,S3) or mOPV3/+bOPV(N1,N2) or nOPV1/+nOPV2/+mOPV3 tOPV(N1,N2,N3) or nOPV1/+nOPV2/+nOPV3

Abbreviations:

OPV, oral poliovirus vaccine; mOPVk, monovalent type k Sabin OPV, where k=1,2 or 3; nOPVk, monovalent type k novel OPV, where k=1,2 or 3;

bOPV, bivalent types 1 and 3 Sabin OPV; tOPV, trivalent types 1, 2 and 3 Sabin OPV; Nk, novel type k, k=1, 2 or 3; Sk, Sabin type k, k=1, 2 or 3;

bOPV(x,y), potential future bivalent types x and y OPV, where x,y=Nk,Sk;

tOPV(x,y,z), potential future trivalent types x, y and z OPV, where x,y,z=Nk,Sk;

/+ replaces “/” which indicates separate doses (when co-administration is not possible) or “+” that implies co-administered doses